MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET

Autor: Mosconi L. 1, 7, Perani D. 3, 4, Sorbi S. 2, Herholz K., 8, Nacmias B. 2, Holthoff V. 10, Salmon E. 11, Baron J.C. 9, De Cristofaro M.T. 1, Padovani A. 5, Borroni B. 6, 9, Franceschi M. 5, Bracco L. 2, Pupi A. 1

Publikováno v: Neurology 63 (2004): 2332–2340.
info:cnr-pdr/source/autori:Mosconi L. 1,7, Perani D. 3,4, Sorbi S. 2, Herholz K., 8, Nacmias B. 2, Holthoff V. 10, Salmon E. 11, Baron J.C. 9, De Cristofaro M.T. 1, Padovani A. 5, Borroni B. 6,9, Franceschi M. 5, Bracco L. 2, Pupi A. 1/titolo:MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET/doi:/rivista:Neurology/anno:2004/pagina_da:2332/pagina_a:2340/intervallo_pagine:2332–2340/volume:63

OBJECTIVES: To investigate whether the combination of fluoro-2-deoxy-d-glucose (FDG) PET measures with the APOE genotype would improve prediction of the conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD). METHOD: After 1 year,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::c087c6336a96af2feba4f4b7df905d4c
https://publications.cnr.it/doc/10269